CAMBRIDGE, Mass., May 2, 2017 /PRNewswire/ -- Merrimack
Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the
company will host its first quarter 2017 investor conference call
and webcast at 8:30 am ET on Wednesday, May 10, 2017.
The call will cover an update on Merrimack's recent progress as
well as a summary of first quarter 2017 financial results. A press
release detailing the information to be discussed on the call will
be issued the morning of Wednesday, May 10,
2017. Investors and the general public are invited to listen
to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394
(international) five minutes prior to the start of the call and
providing the passcode 14613459.
A listen-only webcast of the call will be available in the
Investors section of Merrimack's website, investors.merrimack.com,
and a replay of the call will be archived there for six weeks.
About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking
cancer to ensure that patients and their families live fulfilling
lives. Its mission is to transform cancer care through the smart
design and development of targeted solutions based on the deep
understanding of cancer pathways and biological markers. All of
Merrimack's product candidates, including three in clinical studies
and several others in preclinical development, fit into its
strategy of 1) understanding the biological problems it is trying
to solve, 2) designing specific solutions and 3) developing those
solutions for biomarker-selected patients. This three-pronged
strategy seeks to ensure optimal patient outcomes. For more
information, please visit Merrimack's website at
www.merrimack.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Merrimack constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, as amended. Actual results may differ
materially from those indicated by such forward-looking statements.
Merrimack anticipates that subsequent events and developments will
cause its views to change. However, while Merrimack may elect to
update these forward-looking statements at some point in the
future, Merrimack specifically disclaims any obligation to do
so.
CONTACT:
Geoffrey M. Grande, CFA
617-441-7602
ggrande@merrimack.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/merrimack-announces-timing-of-first-quarter-2017-investor-conference-call-300449924.html
SOURCE Merrimack Pharmaceuticals, Inc.